Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Teva Pharmaceutical Industries Ltd announces FDA approves Teva's SYNRIBO (Omacetaxine Mepesuccinate) for injection for home administration


Monday, 5 May 2014 08:00am EDT 

Teva Pharmaceutical Industries Ltd:FDA approvs SYNRIBO (omacetaxine mepesuccinate) for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and Instructions for Use.With this approval, physicians who treat adults with chronic or accelerated phase CML who are no longer responding to, or who could not tolerate, two or more tyrosine kinase inhibitors (TKIs) will have option to allow their patients to administer SYNRIBO((reg))therapy at home.Teva is working to finalize a comprehensive specialty pharmacy support program which will help facilitate successful home administration of SYNRIBO for HCPs, their patients and caregivers.This program is expected to go live as early as possible in the second quarter of 2014.